R&D | January 06, 2026
Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The move strengthens GBL’s clinical-stage presence in the United States
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The companies aim to expand treatment options for millions living with metabolic disorders
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
Subscribe To Our Newsletter & Stay Updated
